U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of CD8+ CXCR3+ T cells offers potential for a first-in-class targeted systemic ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

Heart disease and breast cancer are two of the most significant health threats facing Black women today. Here's ...

Enrolling the right number and type of patient is crucial Sepsis is a life threatening syndrome initiated by microorganisms.1 Severe and often lethal injuries (eg, shock, multiorgan failure, and ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Not everyone is having a Dry January. But on the heels — and buzzkill — of the surgeon general’s January 3 advisory warning ...

Swollen tongue might signal deeper health concerns. Find out how it could be a warning sign for conditions like nutritional ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Neel Kothari warns of bad science and the 'erosion of trust' between the dental profession and the public as a result of ...